Dash for NASH trips up Gilead, but 'fatty liver disease' remains biotech target
A late-stage clinical trial by Gilead Sciences Inc. failed in fatty liver disease, the company said, sending a blow to a drug industry that has seen treatments for the disease as the next big thing.
The Foster City-based company's (NASDAQ: GILD) study found that only a slightly higher percentage of patients with nonalcoholic steatohepatitis, or NASH, who received a higher dose of a once-a-day oral drug saw an improvement in the disease than those who were given a placebo. Even fewer patients who…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Clinical Trials | Fatty Liver Disease (FLD) | Health Management | Liver | Liver Disease | Study | Urology & Nephrology